Seborrheic dermatitis;Dermatite seborreica

Anais Brasileiros de Dermatologia

Volumn 86, Issue 6, 2011, Pages 1061-1074

  Sampai, Ana Luisa Sobral Bittencourt ^a   Mameri, Ângela Cristina Akel ^b   Vargas, Thiago Jeunon de Sousa ^c   Ramos e Silva, Marcia ^a   Nunes, Amanda Pedreira ^a   Carneiro, Sueli Coelho da Silva ^d  

^a FEDERAL UNIVERSITY OF RIO DE JANEIRO   (Brazil)

^b Dermatology Unit   (Brazil)

^c Hospital Federal de Bonsucesso   (Brazil)

^d STATE UNIVERSITY OF RIO DE JANEIRO   (Brazil)

Author keywords

Dermatitis; Eczema; Seborrheic

Indexed keywords

ANTIFUNGAL AGENT; ANTIHISTAMINIC AGENT; BENZOYL PEROXIDE; CALCINEURIN INHIBITOR; CICLOPIROX; CLOBETASOL PROPIONATE; CORTICOSTEROID; GAMMA INTERFERON; IMIDAZOLE; IMMUNOGLOBULIN G; INTERLEUKIN 10; INTERLEUKIN 12; INTERLEUKIN 8; ITRACONAZOLE; KETOCONAZOLE; METRONIDAZOLE; MONOCYTE CHEMOTACTIC PROTEIN 1; PIMECROLIMUS; PYRITHIONE ZINC; SALICYLIC ACID; SELENIUM SULFIDE; SUCCINATE LITHIUM; TACALCITOL; TACROLIMUS; TERBINAFINE;

ACNE; ACQUIRED IMMUNE DEFICIENCY SYNDROME; ANTIBODY TITER; CHRONIC DISEASE; DIFFERENTIAL DIAGNOSIS; HISTOPATHOLOGY; HLA SYSTEM; HUMAN; IMMUNOGENETICS; MALASSEZIA; MALASSEZIA FURFUR; MALASSEZIA GLOBOSA; MALASSEZIA OBTUSA; MALASSEZIA PACHYDERMATIS; MALASSEZIA RESTRICTA; MALASSEZIA SLOOFFIAE; MALASSEZIA SYMPODIALIS; NATURAL KILLER T CELL; NONHUMAN; PLASMODIUM OVALE; PSORIASIS; REVIEW; ROSACEA; SEBORRHEIC DERMATITIS;

ACQUIRED IMMUNODEFICIENCY SYNDROME; DERMATITIS, SEBORRHEIC; DERMATOMYCOSES; DIAGNOSIS, DIFFERENTIAL; HIV INFECTIONS; HUMANS; MALASSEZIA;

EID: 84856604550     PISSN: 03650596     EISSN: 18064841     Source Type: Journal    
DOI: 10.1590/S0365-05962011000600002     Document Type: Review

References (135)

1. Schechtman RC, Midgley G, Hay RJ. HIV disease and Malassezia yeasts: a quantitative study of patients presenting with seborrhoeic dermatitis. Br J Dermatol. 1995;133:694-8.
2. Gupta AK, Madzia SE, Batra R. Etiology and management of Seborrheic dermatitis. Dermatology. 2004;208:89-93.
3. Inamadar ACPA. The genus Malassezia and human disease. Indian J Dermatol Venereol Leprol. 2003;69:265-70.
4. Moore M. Dermatite seborreica: cultivo do organismo caudador da dermatite produzida experimentalmente. An Bras Dermatol. 1936;11:7-10.
5. Unna P. Das seborrhoische Ekzem. Monatsschr Prakt Dermatol. 1897;6:827-46.
6. Leone R. [Presence and significance of Pityrosporon ovale in pityriasis of the scalp, in figured seborrheic eczema and in various squamous dermatoses. Note III. Cultural, biological and biochemical properties of Pityrosporon ovale, with special reference to the affinity for lipidic substances.]. Minerva Dermatol. 1952;27:123-7.
7. Leone R. [Presence and significance of Pityrosporon ovale in pityriasis of the scalp, in figured seborrheic eczema and in various squamous dermatoses. Note I. Quantitative research on the presence of Pityrosporon ovale in pityriasis of the scalp, in figured seborrheic eczema and in various squamous dermatoses.]. Minerva Dermatol. 1952;27:93-9.
8. Palacky AF, Strycek R. [Modifications in blood proteins in erythroderma and seborrhoeic dermatitis and their relation to biotin deficiency]. Pediatr Listy.1950;5:270-3.
9. Gougerot H, Grupper C, Plas G. [Cutaneous-mucosal ariboflavinosis; rosacea of cornea and medio-facial seborrheic dermatitis.]. Bull Soc Fr Dermatol Syphiligr. 1950;57:277-80.
10. Andrews GC, Post CF, Domonkos AN. Seborrheic dermatitis; supplemental treatment with vitamin B12. N Y State J Med. 1950;50:1921-5.
11. Kiessling W. [Clinical results with internal and intramuscular administration of biotin]. Dermatol Wochenschr. 1951;124:1246-9.
12. Treger J, Moys A, Muzikova M. [Effect of intracutaneous biotin in eczema seborrhoeicum]. Bratisl Lek Listy. 1951;31:562-8.
13. Avcin M. [Dermatitis seborrheica and biotin deficiency in infants]. Zdrav Vestn.1952;21:15-21.
14. Schreiner AW, Rockwell E, Vilter RW. A local defect in the metabolism of pyridoxine in the skin of person with seborrheic dermatitis of the "sicca" type. J Invest Dermatol. 1952;19:95-6.
15. Nisenson A. Seborrheic dermatitis of infants and Leiners's disease: a biotin deficiency. J Pediatr. 1957;51:537-48.
16. Nisenson A, Barness LA. Treatment of seborrheic dermatitis with biotin and vitamin B complex. J Pediatr. 1972;81:630-1.
17. Schwartz RA, Janusz CA, Janniger CK. Seborrheic dermatitis: an overview. Am Fam Physician. 2006;74:125-30.
18. Sudan BJ. Nicotine skin patch treatment and adverse reactions: skin irritation, skin sensitization, and nicotine as a hapten. J Clin Psychopharmacol. 1995;15:145-6.
19. Sudan BJ. Abrogation of facial seborrhoeic dermatitis with homoeopathic high dilutions of tobacco: a new visible model for Benveniste's theory of 'Memory of water'. Med Hypotheses. 1993;41:440-4.
20. Sudan BJ. Ketoconazole, leukotrienes, Paf-acether and nicotine as a hapten: the possible aetiology of seborrhoeic dermatitis. Med Hypotheses. 1987;23:33-8.
21. Sudan BJ. Seborrhoeic dermatitis induced by nicotine of horsetails (Equisetum arvense L.). Contact Dermatitis. 1985;13:201-2.
22. Sudan BJ, Brouillard C, Sterboul J, Sainte-Laudy J. Nicotine as a hapten in seborrhoeic dermatitis. Contact Dermatitis. 1984;11:196-7.
23. Stone OJ. Seborrheic dermatitis--hyperreactive inflammation to saprophytes. Dermatol Int. 1968;7:14-6.
24. Mastrolonardo M, Diaferio A, Logroscino G. Seborrheic dermatitis, increased sebum excretion, and Parkinson's disease: a survey of (im)possible links. Med Hypotheses. 2003;60:907-11.
25. Pierard GE. Seborrheic dermatitis today, gone tomorrow? The link between the biocene and treatment. Dermatology. 2003;206:187-8.
26. Parish LC. L-dopa for seborrheic dermatitis. N Engl J Med. 1970;283:879.
27. Appenzeller O, Harville D. Effect of L-dopa on seborrhea of Parkinsonism. Lancet. 1970;2:311-2.
28. Burton JL, Shuster S. Effect of L-dopa on seborrhoea of Parkinsonism. Lancet. 1970;2:311.
29. Burton JL, Shuster S. Effect of L-dopa on seborrhoea of parkinsonism. Lancet. 1970;2:19-20.
30. Potter J, Wyburn-Mason R. Effect of L-dopa on seborrhoea of parkinsonism. Lancet. 1970;2:660.
31. Wyburn-Mason R. Effect of L-dopa on seborrhoea of parkinsonism. Lancet. 1970;2:154.
32. Martignoni E, Godi L, Pacchetti C, Berardesca E, Vignoli GP, Albani G, et al. Is seborrhea a sign of autonomic impairment in Parkinson's disease? J Neural Transm. 1997;104:1295-304.
33. Binder RL, Jonelis FJ. Seborrheic dermatitis in neuroleptic-induced parkinsonism. Arch Dermatol. 1983;119:473-5.
34. Binder RL, Jonelis FJ. Seborrheic dermatitis: a newly reported side effect of neuroleptics. J Clin Psychiatry. 1984;45:125-6.
35. Moris G, Ribacoba R, Solar DN, Vidal JA. SUNCT syndrome and seborrheic dermatitis associated with craneosynostosis. Cephalalgia. 2001;21:157-9.
36. Rocha N, Velho G, Horta M, Martins A, Massa A. Cutaneous manifestations of familial amyloidotic polyneuropathy. J Eur Acad Dermatol Venereol. 2005;19:605-7.
37. Rubin-Asher D, Zeilig G, Klieger M, Adunsky A, Weingarden H. Dermatological findings following acute traumatic spinal cord injury. Spinal Cord. 2005;43:175-8.
38. Tronnier H. [On an unilaterally localized seborrhoic eczema in syringomyelia.]. Z Haut Geschlechtskr. 1964;37:207-17.
39. Bettley FR, Marten RH. Unilateral seborrheic dermatitis following a nerve lesion. AMA Arch Derm. 1956;73:110-5.
40. Chen TM, Fitzpatrick JE. Unilateral seborrheic dermatitis after decompression of Chiari I malformation and syringomyelia J Am Acad Dermatol. 2006;55:356-7.
41. Ercis M, Balci S, Atakan N. Dermatological manifestations of 71 Down syndrome children admitted to a clinical genetics unit. Clin Genet. 1996;50:317-20.
42. Daneshpazhooh M, Nazemi TM, Bigdeloo L, Yoosefi M. Mucocutaneous findings in 100 children with Down syndrome. Pediatr Dermatol. 2007;24:317-20.
43. Tager A, Berlin C, Schen RJ. Seborrhoeic Dermatitis in Acute Cardiac Disease. Br J Dermatol. 1964;76:367-9.
44. Barba A, Piubello W, Vantini I, Caliari S, Cocchetto R, Vallaperta P, et al. Skin lesions in chronic alcoholic pancreatitis. Dermatologica. 1982;164:322-6.
45. Rao GS. Cutaneous changes in chronic alcoholics. Indian J Dermatol Venereol Leprol. 2004;70:79-81.
46. Naegeli B. [A case from practice (218). Alcoholic sensorimotor polyneuropathy and myopathy in chronic alcoholism. Seborrheic dermatitis]. Schweiz Rundsch Med Prax. 1991;80:650-2.
47. Parish LC, Fine E. Alcoholism and skin disease. Int J Dermatol. 1985;24:300-1.
48. Moore M, Kile RL. Pityrosporum ovalis as a causative agent of seborrheic dermatitis. Science. 1935;81:277-8.
49. Aspiroz MC, Moreno LA, Rubio MC. [Taxonomy of Malassezia furfur: state of the art]. Rev Iberoam Micol. 1997;14:147-9.
50. Guého E MG, Guillot J. The genus Malassezia with description of four new species. Antonie Van Leeuwenhoek. 1996;69:337-55.
51. Goodfield MJ, Saihan EM, Crowley J. Experimental folliculitis with Pityrosporum orbiculare: the influence of host response. Acta Derm Venereol. 1987;67:445-7.
52. Faergemann J. Pityrosporum infections. J Am Acad Dermatol. 1994;31:S18-20.
53. Faergemann J. Pityrosporum ovale and skin diseases. Keio J Med. 1993;42:91-4.
54. Terui T, Kudo K, Tagami H. [Cutaneous immune and inflammatory reactions to Malassezia furfur]. Nihon Ishinkin Gakkai Zasshi. 1999;40:63-7.
55. Faergemann J, Fredriksson T. Tinea versicolor with regard to seborrheic dermatitis. An epidemiological investigation. Arch Dermatol. 1979;115:966-8.
56. McGinley KJ, Leyden JJ, Marples RR, Kligman AM. Quantitative microbiology of the scalp in non-dandruff, dandruff, and seborrheic dermatitis. J Invest Dermatol. 1975;64:401-5.
57. Faergemann J. Tinea versicolor and Pityrosporum orbiculare: mycological investigations, experimental infections and epidemiological surveys. Acta Derm Venereol Suppl (Stockh). 1979:1-23.
58. Bergbrant IM, Faergemann J. Seborrhoeic dermatitis and Pityrosporum ovale: a cultural and immunological study. Acta Derm Venereol. 1989;69:332-5.
59. Bourlond A, Votion V, Armijo F, Minne G. [Pityrosporum ovale in keratotic lesions of seborrheic areas]. Ann Dermatol Venereol. 1984;111:1081-5.
60. Nakabayashi A, Sei Y, Guillot J. Identification of Malassezia species isolated from patients with seborrhoeic dermatitis, atopic dermatitis, pityriasis versicolor and normal subjects. Med Mycol. 2000;38:337-41.
61. Nakabayashi A. [Identification of causative species in malassezia-associated dermatoses]. Nihon Ishinkin Gakkai Zasshi. 2002;43:65-8.
62. Rendic E, Diaz C, Fich F. [Characterization of species of the gender Malassezia in patients with seborrheic dermatitis and subjects without skin lesions]. Rev Med Chil. 2003;131:1295-300.
63. Gupta AK, Kohli Y, Summerbell RC, Faergemann J. Quantitative culture of Malassezia species from different body sites of individuals with or without dermatoses. Med Mycol. 2001;39:243-51.
64. Gaitanis G, Velegraki A, Alexopoulos EC, Chasapi V, Tsigonia A, Katsambas A. Distribution of Malassezia species in pityriasis versicolor and seborrhoeic dermatitis in Greece. Typing of the major pityriasis versicolor isolate M. globosa. Br J Dermatol. 2006;154:854-9.
65. Tajima M, Sugita T, Nishikawa A, Tsuboi R. Molecular analysis of Malassezia microflora in seborrheic dermatitis patients: comparison with other diseases and healthy subjects. J Invest Dermatol. 2008;128:345-51.
66. Nakabayashi A, Sei Y. [Relationship between Malassezia Yeast and Infantile Seborrhoeic Dermatitis]. Nihon Ishinkin Gakkai Zasshi. 2001;42:218-20.
67. Bergbrant IM. Seborrhoeic dermatitis and Pityrosporum ovale: cultural, immunological and clinical studies. Acta Derm Venereol Suppl (Stockh). 1991;167:1-36.
68. Bergbrant IM, Faergemann J. The role of Pityrosporum ovale in seborrheic dermatitis. Semin Dermatol. 1990;9:262-8.
69. Plotkin LI, Squiquera L, Mathov I, Galimberti R, Leoni J. Characterization of the lipase activity of Malassezia furfur. J Med Vet Mycol. 1996;34:43-8.
70. DeAngelis YM, Saunders CW, Johnstone KR, Reeder NL, Coleman CG, Kaczvinsky JR Jr, et al. Isolation and expression of a Malassezia globosa lipase gene, LIP1. J Invest Dermatol. 2007;127:2138-46.
71. Ro BI, Dawson TL. The role of sebaceous gland activity and scalp microfloral metabolism in the etiology of seborrheic dermatitis and dandruff. J Investig Dermatol Symp Proc. 2005;10:194-7.
72. Bergbrant IM. Seborrhoeic dermatitis and Pityrosporum yeasts. Curr Top Med Mycol. 1995;6:95-112.
73. Cowley NC, Farr PM, Shuster S. The permissive effect of sebum in seborrhoeic dermatitis: an explanation of the rash in neurological disorders. Br J Dermatol. 1990;122:71-6.
74. Wishner AJ, Teplitz ED, Goodman DS. Pityrosporum, ketoconazole, and seborrheic dermatitis. J Am Acad Dermatol. 1987;17:140-1.
75. Hay RJ, Graham-Brown RA. Dandruff and seborrhoeic dermatitis: causes and management. Clin Exp Dermatol. 1997;22:3-6.
76. Dawson TL Jr. Malassezia globosa and restricta: breakthrough understanding of the etiology and treatment of dandruff and seborrheic dermatitis through whole-genome analysis. J Investig Dermatol Symp Proc. 2007;12:15-9.
77. Braun-Falco O, Heilgemeir GP, Lincke-Plewig H. [Histological differential diagnosis of psoriasis vulgaris and seborrheic eczema of the scalp]. Hautarzt. 1979;30:478-83.
78. Houck G, Saeed S, Stevens GL, Morgan MB. Eczema and the spongiotic dermatoses: a histologic and pathogenic update. Semin Cutan Med Surg. 2004;23:39-45.
79. Faergemann J. Pityrosporum yeasts--what's new? Mycoses. 1997;40 Suppl 1:29-32.
80. Faergemann J, Bergbrant IM, Dohse M, Scott A, Westgate G. Seborrhoeic dermatitis and Pityrosporum (Malassezia) folliculitis: characterization of inflammatory cells and mediators in the skin by immunohistochemistry. Br J Dermatol. 2001;144:549-56.
81. Parry ME, Sharpe GR. Seborrhoeic dermatitis is not caused by an altered immune response to Malassezia yeast. Br J Dermatol. 1998;139:254-63.
82. Ashbee HR, Fruin A, Holland KT, Cunliffe WJ, Ingham E. Humoral immunity to Malassezia furfur serovars A, B and C in patients with pityriasis versicolor, seborrheic dermatitis and controls. Exp Dermatol. 1994;3:227-33.
83. Neuber K, Kroger S, Gruseck E, Abeck D, Ring J. Effects of Pityrosporum ovale on proliferation, immunoglobulin (IgA, G, M) synthesis and cytokine (IL-2, IL-10, IFN gamma) production of peripheral blood mononuclear cells from patients with seborrhoeic dermatitis. Arch Dermatol Res.1996;288:532-6.
84. Watanabe S, Kano R, Sato H, Nakamura Y, Hasegawa A. The effects of Malassezia yeasts on cytokine production by human keratinocytes. J Invest Dermatol. 2001;116:769-73.
85. Ashbee HR, Ingham E, Holland KT, Cunliffe WJ. Cell-mediated immune responses to Malassezia furfur serovars A, B and C in patients with pityriasis versicolor, seborrheic dermatitis and controls. Exp Dermatol. 1994;3:106-12.
86. Passi S, Morrone A, De Luca C, Picardo M, Ippolito F. Blood levels of vitamin E, polyunsaturated fatty acids of phospholipids, lipoperoxides and glutathione peroxidase in patients affected with seborrheic dermatitis. J Dermatol Sci. 1991;2:171-8.
87. Ianosi S, Stoicescu I, Ianosi G, Neagoe D, Georgescu CV. The study of CD20 and CD45. Ro antibodies in the inflammatory infiltrate involved in acne and seborrheic dermatitis. Rom J Morphol Embryol. 2007;48:285-9.
88. Tsuji K, Nose Y, Ito M, Ozala A, Matsuo I. HLA antigens and susceptibility to psoriasis vulgaris in a non-Caucasian population. Tissue antigens. 1976;8:29-33.
89. Fritsch PO, Reider N. Other Eczematous Eruptions. In: Bolognia JL, Jorizzo JL, Rapini RP, editors. Dermatology. Spain: Mosby Elsevier; 2008. p.197-200.
90. Foley P, Zuo Y, Plunkett A, Merlin K, Marks R. The frequency of common skin conditions in preschool-aged children in Australia: seborrheic dermatitis and pityriasis capitis (cradle cap). Arch Dermatol. 2003;139:318-22.
91. Misery L, Touboul S, Vincot C, Dutray S, Rolland-Jacob G, Consoli SG, et al. [Stress and seborrheic dermatitis]. Ann Dermatol Venereol. 2007;134:833-7.
92. Peyri J, Lleonart M. [Clinical and therapeutic profile and quality of life of patients with seborrheic dermatitis]. Actas Dermosifiliogr. 2007;98:476-82.
93. Sarkar R, Sharma RC, Koranne RV, Sardana K. Erythroderma in children: a clinicoetiological study. J Dermatol. 1999;26:507-11.
94. Sarkar R, Garg VK. Erythroderma in children. Indian J Dermatol Venereol Leprol. 2010;76:341-7.
95. Al-Dhalimi MA. Neonatal and infantile erythroderma: a clinical and follow-up study of 42 cases. J Dermatol. 2007;34:302-7.
96. Cherny S, Mraz S, Su L, Harvell J, Kohler S. Heteroduplex analysis of T-cell receptor gamma gene rearrangement as an adjuvant diagnostic tool in skin biopsies for ery throderma. J Cutan Pathol. 2001;28:351-5.
97. Yamamoto T, Tsuboi R. Interleukin-2-induced seborrhoeic dermatitis-like eruption. J Eur Acad Dermatol Venereol. 2008;22:244-5.
98. Valia RG. Etiopathogenesis of seborrheic dermatitis. Indian J Dermatol Venereol Leprol. 2006;72:253-5.
99. Berger RS, Stoner MF, Hobbs ER, Hayes TJ, Boswell RN. Cutaneous manifestations of early human immunodeficiency virus exposure. J Am Acad Dermatol. 1988;19:298-303.
100. Eisenstat BA, Wormser GP. Seborrheic dermatitis and butterfly rash in AIDS. N Engl J Med. 1984;311:189.
101. Soeprono FF, Schinella RA, Cockerell CJ, Comite SL. Seborrheic-like dermatitis of acquired immunodeficiency syndrome. A clinicopathologic study. J Am Acad Dermatol. 1986;14:242-8.
102. Blanes MBI, Merino E, Portilla J, Sánchez-Payá J, Betlloch I. Current prevalence and characteristics of dermatoses associated with human immunodeficiency virus infection. Actas Dermosifiliogr. 2010;101:702-9.
103. Hakansson C, Faergemann J, Lowhagen GB. Studies on the lipophilic yeast Pityrosporum ovale in HIV-seropositive and HIV-seronegative homosexual men. Acta Derm Venereol. 1988;68:422-6.
104. Schoefer H, Sachs DL, Ochsendorf F. HIV-associated skin and mucocutaneous dis eases. In: Hoffman C, Rockstroh JK, Kamps BS, editors. HIV medicine. 15th ed. Paris, Cagliari, Wuppertal: Flying Publisher: 2007. p.596.
105. Rincón S, Celis A, Sopó L, Motta A, Cepero de García MC. Malassezia yeast species isolated from patients with dermatologic lesions. Biomedica. 2005;25:189-95.
106. Vidal C, Girard PM, Dompmartin D, Bosson JL, Mettra C, Groslambert P, et al. Seborrheic dermatitis and HIV infection. Qualitative analysis of skin surface lipids in men seropositive and seronegative for HIV. J Am Acad Dermatol. 1990;23:1106-10.
107. Passi S, Picardo M, Morrone A, De Luca C, Ippolito F. Skin surface lipids in HIV seropositive and HIV sero-negative patients affected with seborrheic dermatitis. J Dermatol Sci. 1991;2:84-91.
108. Nnoruka EN, Chukwuka JC, Anisuiba B. Correlation of mucocutaneous manifestations of HIV/AIDS infection with CD4 counts and disease progression. Int J Dermatol. 2007;46 Suppl 2:14-8.
109. Dunic I, Vesic S, Jevtovic DJ. Oral candidiasis and seborrheic dermatitis in HIV-infected patients on highly active antiretroviral therapy. HIV Med. 2004;5:50-4.
110. Hardcastle NJ, Tunbridge AJ, Shum KW, Dockrell DH, Green ST. Alopecia in association with severe seborrhoeic dermatitis following combination antiretroviral therapy for acute retroviral syndrome. J Eur Acad Dermatol Venereol. 2005;19:631-3.
111. Smith K, Kuhn L, Coovadia A, Meyers T, Hu CC, Reitz C, et al. Immune reconstitution inflammatory syndrome among HIV-infected South African infants initiating antiretroviral therapy. AIDS. 2009;23:1097-107.
112. Schaub NA, Drewe J, Sponagel L, Gilli L, Courvoisier S, Gyr N, et al. Is there a relation between risk groups or initial CD4 T cell counts and prevalence of seborrheic dermatitis in HIV-infected patients? Dermatology.1999;198:126-9.
113. Prose NS. Cutaneous manifestations of HIV infection in children. Dermatol Clin. 1991;9:543-50.
114. Dann FJ, Tabibian P. Cutaneous diseases in immunodeficiency vírus-infected patients referred to the UCLA Immunossupression skin Clinic: reasons for referral and management of select diseases. Cutis. 1995;55:85-8.
115. Wiwanitkit V. Prevalence of dermatological disorders in Thai HIV-infected patients correlated with different CD4 lymphocyte count statuses: a note on 120 cases. Int J Dermatol. 2004;43:265-8.
116. Elewski B. Safe and effective treatment of seborrheic dermatitis. Cutis. 2009;83:333-8.
117. Satchell AC, Saurajen A, Bell C, Barnetson RS. Treatment of dandruff with 5% tea tree oil shampoo. J Am Acad Dermatol. 2002;47:852-5.
118. Wolwerton SE, editor. Compreensive dermatologic drug therapy. 2nd ed. Philadelphia: Saunders Elsevier; 2007. p.720-3.
119. Wilson J. Hormônios adrenocorticotrófico, esteróides adrenocorticais e seus análogos sintéticos; inibidores da síntese e das ações dos hormônios adrenocorticais In: Hardman JG, Limbird LE, editores. As bases farmacológicas da terapêutica. 9. ed. México-DF: Mc Graw Hill; 1996. p.1099.
120. Faergemann J. Treatment of seborrhoeic dermatitis of the scalp with ketoconazole shampoo. A double-blind study. Acta Derm Venereol. 1990;70:171-2.
121. Hanel H, Smith-Kurtz E, Pastowsky S. [Therapy of seborrheic eczema with an anti fungal agent with an antiphlogistic effect]. Mycoses. 1991;34 Suppl 1:91-3.
122. Reitamo S, Ortonne JP, Sand C, Cambazard F, Bieber T, Fölster-Holst R, et al. A multicentre, randomized, double-blind, controlled study of long-term treatment with 0,1% tacrolimus ointment in adults with moderate to severe atopic dermatitis. Br J Dermatol. 2005;152:1282-9.
123. Rigopoulos D, Ioannides D, Kalogeromitros D, Gregoriou S, Katsambas A. Pimecrolimus cream 1% vs. betamethasone 17-valerate 0.1% cream in the treatment of seborrhoeic dermatitis. A randomized open-label clinical trial. Br J Dermatol. 2004;151:1071-5.
124. Cicek D, Kandi B, Bakar S, Turgut D. Pimecrolimus 1% cream, methylprednisolone aceponate 0.1% cream and metronidazole 0.75% gel in the treatment of seborrhoeic dermatitis: a randomized clinical study. J Dermatolog Treat. 2009;20:344-9.
125. Warshaw EM, Wohlhuter RJ, Liu A, Zeller SA, Wenner RA, Bowers S, et al. Results of a randomized double-blind, vehicle-controlled efficacy trial of pimecrolimus cream 1% for the treatment of moderate to severe facial seborrheic dermatitis. J Am Acad Dermatol. 2007;57:267-64.
126. Ozden MG, Tekin NS, Ilter N, Ankarali H. Topical pimecrolimus 1% for resistent seborrheic dermatitis of the face: an open-label study. Am J Clin Dermatol. 2010;11: 51-4.
127. Shin H, Kwon OS, Won CH, Kim BJ, Lee YW, Choe YB, et al. Clinical efficacies of topical agents for the treatment of seborrheic dermatitis of the scalp: a comparative study. J Dermatol. 2009;36:131-7.
128. Parsad D, Pandhi R, Negi KS, Kumar B. Topical metronidazole in seborrheic dermatitis-a double-blind study. Dermatology. 2001;202:35-7.
129. Nakayama J. Four cases of sebopsoriasis or seborrheic dermatitis of the face and scalp successfully treated with 1a-24 (R)-dihydroxycholecalciferol (tacalcitol) cream. Eur J Dermatol. 2000;10:528-32.
130. Boyle J, Burton JL, Faergemann J. Use of topical lithium succinate for seborrhoeic dermatitis. Br Med J (Clin Res Ed). 1986;292:28.
131. Bonnetblanc JM, De Prost Y, Bazex J, Maignan-Gayrard P. [Treatment of seborrheic dermatitis with benzoyl peroxide]. Ann Dermatol Venereol. 1990;117:123-5.
132. Scaparro E, Quadri G, Virno G, Orifici C, Milani M. Evaluation of the efficacy and tolerability of oral terbinafine (Daskil) in patients with seborrhoeic dermatitis. A multicentre, randomized, investigator-blinded, placebo-controlled trial. Br J Dermatol. 2001 Apr;144(4):854-7.
133. Geissler SE, Michelsen S, Plewig G. Very low dose isotretinoin is effective in controlling seborrhea. J Dtsch Dermatol Ges. 2003;1:952-8.
134. Yu CSM, Stevens G, Liskanich R, Horowitz D. Isotretinoin as monotherapy for sebaceous hyperplasia. J Drugs Dermatol. 2010;9:699-701.
135. Barzilai A, David M, Trau H, Hodak E. Seborrheic dermatitis-like eruption in patients taking isotretinoin therapy for acne: retrospective study of five patients. Am J Clin Dermatol. 2008;9:255-61.